drugset
drugset / Trial / NCT05886439

LK101 Combined With PD-1 or PD-L1 Monoclonal Antibody in the Treatment of Lung Cancer

NCT05886439 ↗

Phase 1/2 Recruiting 60 enrolled Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This is a open lable, single-center phase Ib/IIa study for patients with local advanced or metastastic NSCLC or ES-SCLC, who failed with previous anti-PD-1/PD-L1 therapy (cohort 1 and cohort 2) and for patients with ocal advanced or metastastic NSCLC received the first line treatment (cohort 3). The aim is to observe and evaluate the safety, tolerability and efficacy of LK101 injection combined with pembrolizumab, durvalumab or tislelizumab respectively in the incurable NSCLC and SCLC.

Timeline

Start
2023-05-11
Primary completion
2027-05-30
Completion
2028-05-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Durvalumab Monoclonal antibody 1500 mg Intravenous
Subject LK101 Vaccine — —
Subject Pembrolizumab Monoclonal antibody 200 mg Intravenous
Subject Tislelizumab Monoclonal antibody 200 mg Intravenous

Indications

lung cancer